Circular RNA hsa_circ_0011324 is involved in endometrial cancer progression and the evolution of its mechanism

References

• Braun MM, Overbeek-Wager EA, and Grumbo RJ. Diagnosis and management of endometrial cancer. Am Fam Physician. 2016;93(6):468–474.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2018;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Sarto GE, et al. Continuous combined estrogen plus progestin and endometrial cancer: the women’s health initiative randomized trial. J Natl Cancer Inst. 2016;108(3):djv350.
   PubMedGoogle Scholar
• Zhang C, Wang EY, Liu F, et al. Routine histologic features in complex atypical hyperplasia can predict the presence of endometrial carcinoma: a clinicopathological study of 222 cases. Hum Pathol. 2018;80(40–46):40–46.
   PubMed Web of Science ®Google Scholar
• Chapel DB, Patil SA, Plagov A, et al. Quantitative next-generation sequencing-based analysis indicates progressive accumulation of microsatellite instability between atypical hyperplasia/endometrial intraepithelial neoplasia and paired endometrioid endometrial carcinoma. Mod Pathol. 2019;32(1508–1520):1508–1520.
   PubMed Web of Science ®Google Scholar
• Han L, Du J, Zhao L, et al. An efficacious endometrial sampler for screening endometrial cancer. Front Oncol. 2019;9(67). DOI:10.3389/fonc.2019.00067
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Zhou WY, Cai Z-R, Liu J, et al. Circular RNA: metabolism, functions and interactions with proteins. Mol Cancer. 2020;19(172). DOI:10.1186/s12943-020-01286-3
   Google Scholar
• Shi Y, Jia X, Xu J. The new function of circRNA: translation. Clin Transl Oncol. 2020;22(2162–2169):2162–2169.
   PubMed Web of Science ®Google Scholar
• Qu S, Yang X, Li X, et al. Circular RNA: a new star of noncoding RNAs. Cancer Lett. 2015;365(141–148):141–148.
   PubMed Web of Science ®Google Scholar
• Salzman J. Circular RNA expression: its potential regulation and function. Trends Genet. 2016;32(309–316):309–316.
   PubMed Web of Science ®Google Scholar
• Huang A, Zheng H, Wu Z, et al. Circular RNA-protein interactions: functions, mechanisms, and identification. Theranostics. 2020;10(3503–3517):3503–3517.
   PubMed Web of Science ®Google Scholar
• Jia Y, Liu M, Wang S. CircRNA hsa_circRNA_0001776 inhibits proliferation and promotes apoptosis in endometrial cancer via downregulating LRIG2 by sponging miR-182. Cancer Cell Int. 2020;20(412). DOI:10.1186/s12935-020-01437-y
   Google Scholar
• Wu B, Ren A, Tian Y, et al. Hsa_circ_0075960 serves as a sponge for miR-361-3p/SH2B1 in endometrial carcinoma. Technol Cancer Res Treat. 2020;19(1533033820983079):153303382098307.
   Web of Science ®Google Scholar
• Liu D, Yang Y, Yan A, et al. SPOCD1 accelerates ovarian cancer progression and inhibits cell apoptosis via the PI3K/AKT pathway. Onco Targets Ther. 2020;13(351–359). DOI:10.2147/OTT.S200317
   Google Scholar
• Long MY, Chen, JW, and Zhu, Y, et al. Comprehensive circular RNA profiling reveals the regulatory role of circRNA_0007694 in papillary thyroid carcinoma. Am J Transl Res. 2020;12(4):1362–1378.
   PubMed Web of Science ®Google Scholar
• Xu L, Feng X, Hao X, et al. CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth. J Exp Clin Cancer Res. 2019;38(98). DOI:10.1186/s13046-019-1041-2
   Google Scholar
• Young AP, Jackson DJ, Wyeth RC. A technical review and guide to RNA fluorescence in situ hybridization. PeerJ. 2020;8:e8806.
   PubMed Web of Science ®Google Scholar
• Lu H, Xie X, Wang K, et al. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells. Molecular and Cellular Biochemistry. 2020;475(1–2):63–77.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang N, Zheng X, et al. Circular RNA hsa_circ_0009172 suppresses gastric cancer by regulation of microRNA-485-3p-mediated NTRK3. Cancer Gene Therapy. 2021;28(12):1312–1324.
   PubMed Web of Science ®Google Scholar
• Zhang D, Yi, S, and Cai, B, et al. Involvement of ferroptosis in the granulosa cells proliferation of PCOS through the circRHBG/miR-515/SLC7A11 axis. Ann Transl Med. 2021;9(16):1348. DOI:10.21037/atm-21-4174
   PubMed Web of Science ®Google Scholar
• Xu S, Fu G-B, Tao Z, et al. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget. 2015;6(26457–26471):26457–26471.
   PubMedGoogle Scholar
• Cheng H, Xue, J, and Yang, S, et al. Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development. Oncotarget. 2017;8(29):47984–47997. DOI:10.18632/oncotarget.18207
   PubMedGoogle Scholar
• Lee DE, Brown, JL, and Rosa, ME, et al. microRNA-16 is downregulated during insulin resistance and controls skeletal muscle protein accretion. J Cell Biochem. 2016;117(8):1775–1787.
   PubMed Web of Science ®Google Scholar
• Kalinkova L, Kajo K, Karhanek M, et al. Discriminating miRNA profiles between endometrioid well- and poorly-differentiated tumours and endometrioid and serous subtypes of endometrial cancers. Int J Mol Sci. 2020;21(17):6071.
   PubMed Web of Science ®Google Scholar
• He Y, Xu S, Qi Y, et al. Long noncoding RNA SNHG25 promotes the malignancy of endometrial cancer by sponging microRNA-497-5p and increasing FASN expression. J Ovarian Res. 2021;14(163). DOI:10.1186/s13048-021-00906-w
   Google Scholar
• Kumari P, Sharma I, Saha SC, et al. Diagnostic potential of differentially regulated microRNAs among endometriosis, endometrioid ovarian cancer, and endometrial cancer. J Cancer Res Ther. 2021;17(1003–1011):1003–1011.
   PubMed Web of Science ®Google Scholar
• Aoki Y, Kanao H, Wang X, et al. Adjuvant treatment of endometrial cancer today. Jpn J Clin Oncol. 2020;50(753–765):753–765.
   PubMed Web of Science ®Google Scholar
• Barcellini A, Roccio M, Laliscia C, et al. Endometrial cancer: when upfront surgery is not an option. Oncology. 2021;99(65–71):65–71.
   PubMed Web of Science ®Google Scholar
• Shi Y, He, R, and Yang, Y, et al. Circular RNAs: novel biomarkers for cervical, ovarian and endometrial cancer (Review). Oncol Rep. 2020;44(5):1787–1798. DOI:10.3892/or.2020.7780
   PubMed Web of Science ®Google Scholar
• Cheng DL, Xiang YY, Ji LJ, et al. Competing endogenous RNA interplay in cancer: mechanism, methodology, and perspectives. Tumour Biol. 2015;36(2):479–488.
   PubMedGoogle Scholar
• Wang Y, Yin L, Sun X. CircRNA hsa_circ_0002577 accelerates endometrial cancer progression through activating IGF1R/PI3K/Akt pathway. J Exp Clin Cancer Res. 2020;39(169). DOI:10.1186/s13046-020-01679-8
   Google Scholar
• Zong ZH, Liu Y, Chen S, et al. Circ_PUM1 promotes the development of endometrial cancer by targeting the miR-136/NOTCH3 pathway. J Cell Mol Med. 2020;24(4127–4135):4127–4135.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chang Y, Cai Y. Circ_0067835 sponges miR-324-5p to induce HMGA1 expression in endometrial carcinoma cells. J Cell Mol Med. 2020;24(13927–13937):13927–13937.
   PubMed Web of Science ®Google Scholar
• Fridrichova I, Kalinkova L, Karhanek M, et al. miR-497-5p decreased expression associated with high-risk endometrial cancer. Int J Mol Sci. 2020;22(1):127.
   PubMed Web of Science ®Google Scholar
• Hu J, Peng X, Du W, et al. circSLC6A6 sponges miR-497-5p to promote endometrial cancer progression via the PI4KB/Hedgehog axis. J Immunol Res. 2021;2021(5512391):1–13.
   Google Scholar
• Roncolato F, Lindemann K, Willson ML, et al. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. 2019;10(CD012160). DOI:10.1002/14651858.CD012160.pub2
   PubMedGoogle Scholar
• Zhou X, Chen Z, Pei L, et al. MicroRNA miR-106a-5p targets forkhead box transcription factor FOXC1 to suppress the cell proliferation, migration, and invasion of ectopic endometrial stromal cells via the PI3K/Akt/mTOR signaling pathway. Bioengineered. 2021;12(2203–2213). DOI:10.1080/21655979.2021.1933679
   Google Scholar
• Barra F, Evangelisti, G, and Ferro Desideri, L, et al. Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer. Expert Opin Investig Drugs. 2019;28(2):131–142.
   PubMed Web of Science ®Google Scholar